GSK Looks To Capitalize On AstraZeneca’s Anemia Drug Knock-Back

Safety Profile Will Be Battleground

 
• By Andrew McConaghie

AstraZeneca and FibroGen hit another safety roadblock with roxadustat, while GSK is hoping it might catch up with its rivals in the US.

Entrance to FDA headquarters in Maryland
After a near-unanimous vote against approval from experts, the US FDA looks likely to reject roxadustat.

More from Business

More from Scrip